Crescent Biopharma, Inc.

CBIONASDAQHealthcareBiotechnology

$12.76- (-)1Y +2.74%

As of Oct 26, 2026 close

Market cap: $426.47M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $8.72$27.41
Volume (live): -
Avg. volume (3M): 458.61K

Crescent Biopharma, Inc. (CBIO) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Crescent Biopharma, Inc. stock.

Analyst Consensus Rating

Investment consensus from 6 professional research analysts

Consensus Rating

Buy

Based on 6 unique analysts

(10 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$30.17

+136.44% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest CBIO Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 19, 2026	Mitchell Kapoor	HC Wainwright	Reiterates	Buy	$36.00
Oct 16, 2026	Stephen Willey	Stifel Nicolaus	Reiterates	Buy	$28.00
Oct 16, 2026	Unknown Analyst	Wedbush	Initiates	Buy	$27.00
Oct 16, 2026	Biren Amin	Piper Sandler	Maintains	Buy	$35.00
Oct 6, 2026	Stephen Willey	Stifel Nicolaus	Maintains	Buy	$28.00
Oct 6, 2026	Mitchell Kapoor	HC Wainwright	Upgrades	Buy	$36.00
Oct 5, 2026	Charles Zhu	LifeSci Capital	Maintains	Buy	$28.00
Sep 14, 2026	Robert Driscoll	Wedbush	Maintains	Buy	$27.00
Jul 31, 2026	Stephen Willey	Stifel Nicolaus	Maintains	Buy	$30.00 → $28.00 −2.00 (−6.7%)
Jul 31, 2026	Mitchell Kapoor	HC Wainwright	Reiterates	Hold	-

Mitchell Kapoor

HC Wainwright

BuyReiterates

$36.00

Oct 19

Stephen Willey

Stifel Nicolaus

BuyReiterates

$28.00

Oct 16

Unknown Analyst

Wedbush

BuyInitiates

$27.00

Oct 16

Biren Amin

Piper Sandler

BuyMaintains

$35.00

Oct 16

Stephen Willey

Stifel Nicolaus

BuyMaintains

$28.00

Oct 6

Mitchell Kapoor

HC Wainwright

BuyUpgrades

$36.00

Oct 6

Charles Zhu

LifeSci Capital

BuyMaintains

$28.00

Oct 5

Robert Driscoll

Wedbush

BuyMaintains

$27.00

Sep 14

Stephen Willey

Stifel Nicolaus

BuyMaintains

$30.00 → $28.00

Jul 31

Mitchell Kapoor

HC Wainwright

HoldReiterates

Jul 31

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 19, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for CBIO?

The analyst consensus rating for CBIO is Buy, based on the latest ratings from 6 analysts over the last 90 days.

What is the average price target for CBIO?

The average 12-month price target for CBIO is $30.17, representing an upside of 136.4% from the Oct 26, 2026 close of $12.76.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.